Sangamo Therapeutics (SGMO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist

2.700
-0.170-5.92%

Close Nov 11 16:00 ET

2.470
-0.230-8.52%

Pre 06:14 ET

562.20MMarket Cap-1956P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: SGMO to Report Financial Results Post-market on November 12
Moomoo NewsNov 6 20:00 ET
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Raises Target Price to $10
Moomoo NewsNov 5 06:36 ET · Ratings
Express News | Sangamo Therapeutics Inc : H.c. Wainwright Raises Target Price to $10 From $5
ReutersNov 5 06:12 ET
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
BusinesswireNov 4 16:15 ET
Individual Investors Who Own 55% Along With Institutions Invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Saw Increase in Their Holdings Value Last Week
Yahoo FinanceNov 1 07:34 ET
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
BenzingaOct 25 14:09 ET

Comments

BigAlMoney

10 hours ago

$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...